Velakast (Velakast) is a modern combined drug for the treatment of chronic hepatitis C in adults. It contains two active components: sofosbuvir at a dosage of 400 mg and velpatasvir at a dosage of 100 mg.

The drug is used for the treatment of hepatitis C of all genotypes (1, 2, 3, 4, 5, and 6). It is prescribed for patients without cirrhosis, with compensated cirrhosis, HCV/HIV coinfection, and in cases where previous therapies have been ineffective.

The recommended dosage is one tablet once daily with a meal, taken with water. The treatment course for patients without cirrhosis is 12 weeks (84 days), while patients with cirrhosis should also receive 12 weeks of treatment, but in some cases, such as genotype 3, the treatment may be extended to 24 weeks.

Contraindications: hypersensitivity to the components of the drug, age under 18, pregnancy, and breastfeeding. The drug should be taken with caution in case of severe renal insufficiency, decompensated cirrhosis, in the elderly (over 65 years of age), and in case of use of amiodarone.

Possible side effects: fatigue, weakness, headache, nausea, insomnia, diarrhea, and irritability.